AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors
AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer March 18, 2026 08:36 ET | Source: AIM ImmunoTech Inc. OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s












